Bristol Myers Squibb already has a cancer program targeting the TIGIT protein, but in acquiring rights to Agenus’s drug, the pharma giant adds a bispecific antibody that preclinical research suggests has the potential to be the best in this drug class. BMS agreed to pay $200 million up front for global rights.
Experts weighed in on how the move could change the way drugmakers raise money for development programs. But as digital securities as a financial instrument gain traction, they could carry potential risks too.
Munck Wilson Mandala Partner Greg Howison shared his perspective on some of the legal ramifications around AI, IP, connected devices and the data they generate, in response to emailed questions.
The drugmaker called its offering, scheduled for next month and meant to finance development of the drug AGEN2034, a first in healthcare and said it expects others to use the same means to raise capital.
Many companies are contending to hit the market first in the race for a genital herpes vaccine. The thread that ties them together? Immunotherapy – the wunderdrug for cancer therapy that’s now showing promise for infectious disease. But it hasn’t always been so, said Agenus CEO Garo Armen, whose immunotherapy approach in both cancer and in infectious disease […]
Cambridge pharmaceutical maker Genocea remains at the head of the herpes vaccine pack, having newly released another set of positive results for its experimental HSV2 vaccine. The company has found that its herpes vaccine is effective even a year after the initial dosage – cutting down the genital lesion and viral shedding rates substantially over a significant time […]
After decades of stagnancy in the herpes therapeutics space, a real neck-and-neck race is emerging among three biotechs in the immunotherapy space: Genocea and Agenus, both based in Massachusetts, San Diego’s Vical are speeding ahead in developing a herpes vaccine. The idea for these companies is to develop a therapeutic vaccine targeted toward individuals who already have […]
At the Abarca Forward conference earlier this year, George Van Antwerp, managing director at Deloitte, discussed how social determinants of health and a personalized member experience can improve medication adherence and health outcomes.